Drug Manufacturing

ReiThera receives AIFA approval to open new production facility in Italy

Italian Medicines Agency (AIFA) has granted operational authorisation to biotech company ReiThera to open its new production area at its pharmaceutical facility located at the Castel Romano Technopole.

CSL and Translational Sciences sign license deal for thrombus dissolving drug

Global biotechnology firm CSL has signed a strategic option and license deal with biopharmaceutical company Translational Sciences for thrombus dissolving drug candidate, TS23.

Celregen signs license deal with Cellusion for bullous keratopathy therapy

Shanghai Fosun Pharmaceutical’s member Hangzhou Celregen Therapeutics has entered into an exclusive license agreement with Japanese regenerative medicine start-up Cellusion for CLS001.

Evaxion, UMass Chan receive grant from NIH to develop gonorrhea vaccine

Evaxion Biotech, along with UMass Chan Medical School, has received a funding from the US National Institutes of Health (NIH) to develop a lead vaccine candidate to treat gonorrhea.

CARsgen releases first CAR T cells batch from North Carolina facility

CARsgen Therapeutics has announced the start of production at its Current Good Manufacturing Practice (CGMP) manufacturing facility in North Carolina, US and released the first CAR T cells batch for clinical trials.

BioDuro-Sundia and X-Chem launch DEL technology services in China

BioDuro-Sundia and X-Chem have collaborated to launch the DNA encoded compound library (DEL) technology services in China for the discovery of new small molecule drugs.

Roche, Genentech sign license deal with Kiniksa for vixarelimab

Kiniksa Pharmaceuticals has entered into a global license agreement with Roche and its subsidiary, Genentech, for the development and commercialisation of an investigational fully human monoclonal antibody, vixarelimab.

ViiV Healthcare, Medicines Patent Pool partner to expand HIV drug access

ViiV Healthcare and the Medicines Patent Pool (MPP) have entered into a voluntary licensing agreement to expand access to cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP).

Procaps Group signs agreement to buy Grupo Somar

Procaps Group, an integrated LatAm healthcare and pharmaceutical conglomerate, has signed a definitive agreement to buy Grupo Somar, which includes Grupo Farmacéutico Somar and Química y Farmacia and, Gelcaps and associated entities from Advent International, a private equity investor.